ClinicalTrials.gg
Not yet recruitingNCT07915232PETUNIAUpdated Nov 4, 2026

A Study to Assess Pregnancy, Neonatal and Infant Outcomes in Participants Exposed to Nipocalimab

An observational study in Pregnancy Related, Pregnancy and Pregnancy High-risk, sponsored by Janssen Research & Development, LLC. Not yet recruiting. Open to female participants. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Observational

Updated Nov 4, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
162
Sex
Female
01

Study summary

The purpose of this study is to find out how often:

  • Pregnancy problems, complications in mothers, and health issues in newborn babies occurred in participants who took nipocalimab just before or during pregnancy.
  • Serious infections occur in newborns and infants born to participants who took nipocalimab just before or during pregnancy.
  • Babies are born with major birth defects (not related to chromosomes) in pregnancies where nipocalimab was taken just before or during pregnancy.
02

Conditions studied

  • Pregnancy Related
  • Pregnancy
  • Pregnancy High-risk
03

In context

Lead sponsor

Janssen Research & Development, LLC is the lead sponsor of 933 studies on the registry; 77 are open to participants now.

Of its 285 completed or terminated interventional studies of FDA-regulated products, 137 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The study population are cases reported to the Company global safety database from post-marketing reports of exposure to nipocalimab during pregnancy.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- Documented exposure to least one dose of nipocalimab any time immediately before ( 1 week [7 days ] before estimated date of conception) or during pregnancy in the post-marketing setting

Exclusion criteria

Exclusion Criteria:

  • Reports in which the pregnant person discontinued nipocalimab 1 week (7 days) before the estimated date of conception
  • Indirect case reports (reported by someone other than the patient or the health care provider [HCP]) for which the reporter refuses to provide follow-up information, and the participants or HCP cannot be identified based on the information provided
  • Case lacking reporter contact details
  • Cases where only the father/male partner is exposed to nipocalimab during partner's pregnancy
  • Cases occurring in an interventional setting (that is, clinical trials)
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
162 participants (estimated)
Patient registry
No

Groups and cohorts

  • Participants Exposed to Nipocalimab Immediately Before or During Pregnancy

    Participants with documented exposure to at least one dose of nipocalimab any time immediately before (within 1 week \[7 days\] before estimated date of conception) or during pregnancy in the post-marketing setting. No drug will be administered as a part of this study. Participants received nipocalimab as per their routine clinical practice settings.

06

What researchers measure

Primary outcomes

  1. Prevalence of Fetal Growth Restriction

    A fetus with an estimated fetal weight less than the 10th percentile for gestational age based upon a population reference or standard.

    Time frame: During pregnancy (Up to Week 42)

  2. Prevalence of Small for Gestational Age

    A newborn with a birthweight less than the 10th percentile for gestational age based upon a population reference or standard.

    Time frame: At birth

  3. Prevalence of Hypertensive Disorders of Pregnancy

    Hypertensive disorder of pregnancy (that is, preeclampsia, gestational hypertension, hemolysis, elevated liver enzymes, and low platelet count (HELLP) syndrome, or eclampsia).

    Time frame: From 20 weeks gestation through 6 weeks postpartum

  4. Prevalence of Placental Abruption

    A condition in which the placenta has begun to separate from the uterus before the fetus is born.

    Time frame: During pregnancy (Up to Week 42)

  5. Prevalence of Serious Infections in Neonates

    Infections resulting in a hospitalization that occur within the first 27 days of life (0-27 days).

    Time frame: Birth to 27 days

  6. Prevalence of Serious Infections in Infants

    Infections resulting in a hospitalization that occur between 28 and 365 days of life.

    Time frame: 28 days to 365 days after birth

  7. Prevalence of Non-chromosomal Major Congenital Malformations

    Congenital abnormality that requires medical or surgical treatment, has a serious adverse effect on health and development, or has significant cosmetic impact, excluding those that are chromosomal or Mendelian-inherited anomalies.

    Time frame: During pregnancy (up to Week 42) and up to 1 year after birth

Secondary outcomes

  1. Prevalence of Live Birth

    Delivery of a live newborn.

    Time frame: At Delivery

  2. Prevalence of Spontaneous Abortion

    Clinically detected pregnancy loss before 20 completed weeks of gestation that occurs without medical or surgical intervention to terminate the pregnancy.

    Time frame: Prior to 20 weeks gestation

  3. Prevalence of Stillbirth

    Fetus born dead at \>= 20 weeks gestation or weighing \>= 350 grams. Fetal death occurring \> 20 weeks but less than 28 weeks gestation is considered an early fetal loss. Fetal death occurring \> 28 weeks is considered a late fetal loss. If gestational age is unknown, stillbirth refers to a fetus weighing \>= 350 grams.

    Time frame: At or after 20 completed weeks of gestation

  4. Prevalence of Preterm Birth

    Delivery of a viable infant before 37 completed weeks of gestation.

    Time frame: Prior to 37 completed weeks of gestation

  5. Prevalence of Intrapartum Hemorrhage

    Maternal complication characterized by significant blood loss occurring during pregnancy.

    Time frame: During pregnancy (Up to 42 weeks)

  6. Prevalence of Postpartum Hemorrhage

    Maternal complication characterized by significant blood loss occurring after pregnancy.

    Time frame: At Birth and after 12 weeks delivery

  7. Prevalence of Neonatal Death

    Death that occurs within the first 27 days of life (0-27 days).

    Time frame: Birth to 27 days

  8. Prevalence of Infant Death

    Death that occurs between 28 and 365 days of life.

    Time frame: 28 days to 365 days after birth

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — The data sharing policy of Johnson \& Johnson Innovative Medicine is available at www.jnj.com/innovativemedicine/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Data sharing details ↗ · www.jnj.com

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Nov 2026; primary completion for Apr 2036, 113 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 30, 2026
First posted
Nov 4, 2026
StartEst.
Nov 30, 2026
Primary completionEst.
Apr 30, 2036
CompletionEst.
Apr 30, 2036
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07915232
Responsible party
Sponsor
First posted
Nov 4, 2026
Start date
Nov 30, 2026 (estimated)
Primary completion
Apr 30, 2036 (estimated)
Completion
Apr 30, 2036 (estimated)
Last update
Nov 4, 2026

Study contacts

Study Contact
Contact
Participate-In-This-Study1@its.jnj.com
844-434-4210
Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion